FDA takes a pass on pegvaliase panel; Flexion terminates an old AstraZeneca pact

BioMarin says that the FDA is indicating that it won’t be holding a panel review for pegvaliase as a new treatment for phenylketonuria (PKU). That is likely to somewhat improve its odds of success, with a priority review and a PDUFA date of February 28, 2018.

Flexion Therapeutics has sent a notice to AstraZeneca terminating their deal on FX005’s sustained-release p38 MAP, or mitogen-activated protein, kinase inhibitor development program. Flexion has dumped the drug from its pipeline.

⇨ Canada’s AbCellera Biologics has forged a deal with GSK where it will apply its high-throughput single-cell antibody screening platform to identify antibodies against an undisclosed membrane protein target.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 30,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Convergence 2018

Technical Operations Manager
Molecular Templates Austin, TX
Senior Director, Global Commercial Strategy, Rare Disease
Govig BioPharma/Aeglea BioTherapeutics Austin, TX
Senior Manager, Sales & Client Development
Aldevron Boston or San Francisco
Scientist, Cellular Immunology
Codiak BioSciences Cambridge, MA
Director of Quality Assurance
Aldevron Fargo, ND
Principal Scientist, Immuno-Oncology (Inflammation)
Codiak BioSciences Cambridge, MA

Visit Endpoints Careers ->